CA2935954A1 - Factor viii chimeric proteins and uses thereof - Google Patents
Factor viii chimeric proteins and uses thereof Download PDFInfo
- Publication number
- CA2935954A1 CA2935954A1 CA2935954A CA2935954A CA2935954A1 CA 2935954 A1 CA2935954 A1 CA 2935954A1 CA 2935954 A CA2935954 A CA 2935954A CA 2935954 A CA2935954 A CA 2935954A CA 2935954 A1 CA2935954 A1 CA 2935954A1
- Authority
- CA
- Canada
- Prior art keywords
- seq
- fviii
- protein
- chimeric protein
- domain
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 108020001507 fusion proteins Proteins 0.000 title claims abstract description 305
- 102000037865 fusion proteins Human genes 0.000 title claims abstract description 305
- 229960000301 factor viii Drugs 0.000 title claims description 27
- 150000001413 amino acids Chemical class 0.000 claims abstract description 494
- 102100036537 von Willebrand factor Human genes 0.000 claims abstract description 304
- 108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 240
- 229920001184 polypeptide Polymers 0.000 claims abstract description 232
- 102000004196 processed proteins & peptides Human genes 0.000 claims abstract description 231
- 108010009817 Immunoglobulin Constant Regions Proteins 0.000 claims abstract description 141
- 102000009786 Immunoglobulin Constant Regions Human genes 0.000 claims abstract description 140
- 101000911390 Homo sapiens Coagulation factor VIII Proteins 0.000 claims abstract description 99
- 102100026735 Coagulation factor VIII Human genes 0.000 claims abstract description 78
- 239000013598 vector Substances 0.000 claims abstract description 47
- 238000000034 method Methods 0.000 claims abstract description 42
- 235000001014 amino acid Nutrition 0.000 claims description 532
- 108090000623 proteins and genes Proteins 0.000 claims description 263
- 108010047303 von Willebrand Factor Proteins 0.000 claims description 260
- 102000004169 proteins and genes Human genes 0.000 claims description 237
- 235000018102 proteins Nutrition 0.000 claims description 236
- 238000003780 insertion Methods 0.000 claims description 163
- 230000037431 insertion Effects 0.000 claims description 163
- 229960001134 von willebrand factor Drugs 0.000 claims description 156
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 133
- 230000027455 binding Effects 0.000 claims description 100
- 238000003776 cleavage reaction Methods 0.000 claims description 84
- 239000012634 fragment Substances 0.000 claims description 84
- 230000007017 scission Effects 0.000 claims description 84
- 102000040430 polynucleotide Human genes 0.000 claims description 66
- 108091033319 polynucleotide Proteins 0.000 claims description 66
- 239000002157 polynucleotide Substances 0.000 claims description 66
- 208000032843 Hemorrhage Diseases 0.000 claims description 54
- 210000004027 cell Anatomy 0.000 claims description 47
- 125000000539 amino acid group Chemical group 0.000 claims description 43
- 208000034158 bleeding Diseases 0.000 claims description 41
- 238000006467 substitution reaction Methods 0.000 claims description 41
- 230000000740 bleeding effect Effects 0.000 claims description 40
- 102000002110 C2 domains Human genes 0.000 claims description 39
- 108050009459 C2 domains Proteins 0.000 claims description 39
- 108090000190 Thrombin Proteins 0.000 claims description 36
- 229960004072 thrombin Drugs 0.000 claims description 36
- 230000002378 acidificating effect Effects 0.000 claims description 34
- 241000699670 Mus sp. Species 0.000 claims description 31
- 102000001690 Factor VIII Human genes 0.000 claims description 27
- 108010054218 Factor VIII Proteins 0.000 claims description 27
- 230000001965 increasing effect Effects 0.000 claims description 25
- 208000014674 injury Diseases 0.000 claims description 24
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 22
- 239000000203 mixture Substances 0.000 claims description 21
- 108010076504 Protein Sorting Signals Proteins 0.000 claims description 20
- 102000005962 receptors Human genes 0.000 claims description 20
- 108020003175 receptors Proteins 0.000 claims description 20
- 238000011282 treatment Methods 0.000 claims description 16
- 239000004365 Protease Substances 0.000 claims description 14
- 102000035195 Peptidases Human genes 0.000 claims description 13
- 108091005804 Peptidases Proteins 0.000 claims description 13
- 108010022052 Proprotein Convertase 5 Proteins 0.000 claims description 11
- 230000008733 trauma Effects 0.000 claims description 10
- 108010029144 Factor IIa Proteins 0.000 claims description 9
- 108010074860 Factor Xa Proteins 0.000 claims description 9
- 230000004913 activation Effects 0.000 claims description 9
- 239000000178 monomer Substances 0.000 claims description 9
- 108010029485 Protein Isoforms Proteins 0.000 claims description 8
- 102000001708 Protein Isoforms Human genes 0.000 claims description 8
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 claims description 8
- 235000018417 cysteine Nutrition 0.000 claims description 8
- 210000003205 muscle Anatomy 0.000 claims description 8
- 238000007911 parenteral administration Methods 0.000 claims description 8
- 239000004475 Arginine Substances 0.000 claims description 7
- 108010048049 Factor IXa Proteins 0.000 claims description 7
- 201000003542 Factor VIII deficiency Diseases 0.000 claims description 7
- 208000009292 Hemophilia A Diseases 0.000 claims description 7
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 claims description 7
- 238000001356 surgical procedure Methods 0.000 claims description 7
- 206010053567 Coagulopathies Diseases 0.000 claims description 6
- 102100027995 Collagenase 3 Human genes 0.000 claims description 6
- 108050005238 Collagenase 3 Proteins 0.000 claims description 6
- 108010080805 Factor XIa Proteins 0.000 claims description 6
- 108060005987 Kallikrein Proteins 0.000 claims description 6
- 102000001399 Kallikrein Human genes 0.000 claims description 6
- 102100027998 Macrophage metalloelastase Human genes 0.000 claims description 6
- 101710187853 Macrophage metalloelastase Proteins 0.000 claims description 6
- 102100030219 Matrix metalloproteinase-17 Human genes 0.000 claims description 6
- 108090000585 Matrix metalloproteinase-17 Proteins 0.000 claims description 6
- 102100029693 Matrix metalloproteinase-20 Human genes 0.000 claims description 6
- 108090000609 Matrix metalloproteinase-20 Proteins 0.000 claims description 6
- 102100033174 Neutrophil elastase Human genes 0.000 claims description 6
- 208000035475 disorder Diseases 0.000 claims description 6
- 210000004962 mammalian cell Anatomy 0.000 claims description 6
- 108090000155 pancreatic elastase II Proteins 0.000 claims description 6
- 108010013369 Enteropeptidase Proteins 0.000 claims description 5
- 102100029727 Enteropeptidase Human genes 0.000 claims description 5
- 108010054265 Factor VIIa Proteins 0.000 claims description 5
- 108010071241 Factor XIIa Proteins 0.000 claims description 5
- 102000001398 Granzyme Human genes 0.000 claims description 5
- 108060005986 Granzyme Proteins 0.000 claims description 5
- 241001465754 Metazoa Species 0.000 claims description 5
- 101800001491 Protease 3C Proteins 0.000 claims description 5
- 229940012414 factor viia Drugs 0.000 claims description 5
- 238000001990 intravenous administration Methods 0.000 claims description 5
- 229910052751 metal Inorganic materials 0.000 claims description 5
- 239000002184 metal Substances 0.000 claims description 5
- 230000000069 prophylactic effect Effects 0.000 claims description 5
- 108090000250 sortase A Proteins 0.000 claims description 5
- 208000010392 Bone Fractures Diseases 0.000 claims description 4
- 206010072043 Central nervous system haemorrhage Diseases 0.000 claims description 4
- 208000012671 Gastrointestinal haemorrhages Diseases 0.000 claims description 4
- 206010018985 Haemorrhage intracranial Diseases 0.000 claims description 4
- 206010061249 Intra-abdominal haemorrhage Diseases 0.000 claims description 4
- 208000008574 Intracranial Hemorrhages Diseases 0.000 claims description 4
- 206010028024 Mouth haemorrhage Diseases 0.000 claims description 4
- 208000009613 Oral Hemorrhage Diseases 0.000 claims description 4
- 230000000903 blocking effect Effects 0.000 claims description 4
- 208000015294 blood coagulation disease Diseases 0.000 claims description 4
- 230000009852 coagulant defect Effects 0.000 claims description 4
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 claims description 4
- 230000009977 dual effect Effects 0.000 claims description 4
- 208000030304 gastrointestinal bleeding Diseases 0.000 claims description 4
- 125000003630 glycyl group Chemical group [H]N([H])C([H])([H])C(*)=O 0.000 claims description 4
- 208000002085 hemarthrosis Diseases 0.000 claims description 4
- 238000007913 intrathecal administration Methods 0.000 claims description 4
- 210000000574 retroperitoneal space Anatomy 0.000 claims description 4
- 102000014452 scavenger receptors Human genes 0.000 claims description 4
- 108010078070 scavenger receptors Proteins 0.000 claims description 4
- 238000007920 subcutaneous administration Methods 0.000 claims description 4
- 238000011200 topical administration Methods 0.000 claims description 4
- 108060003951 Immunoglobulin Proteins 0.000 claims description 3
- 102000018358 immunoglobulin Human genes 0.000 claims description 3
- 238000004519 manufacturing process Methods 0.000 claims description 3
- 230000000087 stabilizing effect Effects 0.000 claims description 3
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 2
- 210000004978 chinese hamster ovary cell Anatomy 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 238000007918 intramuscular administration Methods 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims description 2
- 102220359803 c.10G>A Human genes 0.000 claims 5
- 239000002773 nucleotide Substances 0.000 abstract description 38
- 125000003729 nucleotide group Chemical group 0.000 abstract description 38
- 229940024606 amino acid Drugs 0.000 description 467
- 125000005647 linker group Chemical group 0.000 description 139
- 102100026120 IgG receptor FcRn large subunit p51 Human genes 0.000 description 77
- 150000007523 nucleic acids Chemical class 0.000 description 32
- 238000012217 deletion Methods 0.000 description 24
- 230000037430 deletion Effects 0.000 description 24
- 230000014509 gene expression Effects 0.000 description 24
- 102000039446 nucleic acids Human genes 0.000 description 24
- 108020004707 nucleic acids Proteins 0.000 description 23
- 102000004961 Furin Human genes 0.000 description 22
- 108090001126 Furin Proteins 0.000 description 22
- 230000006870 function Effects 0.000 description 22
- 230000035772 mutation Effects 0.000 description 22
- 108091026890 Coding region Proteins 0.000 description 21
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 20
- 230000000694 effects Effects 0.000 description 20
- 102000057593 human F8 Human genes 0.000 description 20
- 239000000047 product Substances 0.000 description 20
- 108091028043 Nucleic acid sequence Proteins 0.000 description 17
- 238000013518 transcription Methods 0.000 description 17
- 230000035897 transcription Effects 0.000 description 17
- 238000012545 processing Methods 0.000 description 16
- 208000027418 Wounds and injury Diseases 0.000 description 14
- 230000006378 damage Effects 0.000 description 14
- 230000003993 interaction Effects 0.000 description 14
- 238000013519 translation Methods 0.000 description 14
- 238000005345 coagulation Methods 0.000 description 13
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 13
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 12
- 108020004414 DNA Proteins 0.000 description 12
- 102100036365 Proprotein convertase subtilisin/kexin type 5 Human genes 0.000 description 12
- 210000004369 blood Anatomy 0.000 description 12
- 239000008280 blood Substances 0.000 description 12
- 230000015271 coagulation Effects 0.000 description 12
- 238000001727 in vivo Methods 0.000 description 12
- -1 isopentanyl Chemical group 0.000 description 12
- 239000013612 plasmid Substances 0.000 description 12
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 11
- 235000004279 alanine Nutrition 0.000 description 11
- 102000004190 Enzymes Human genes 0.000 description 10
- 108090000790 Enzymes Proteins 0.000 description 10
- 239000004471 Glycine Substances 0.000 description 10
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 10
- 238000003556 assay Methods 0.000 description 10
- 230000035602 clotting Effects 0.000 description 10
- 229940088598 enzyme Drugs 0.000 description 10
- 230000004927 fusion Effects 0.000 description 10
- 230000003834 intracellular effect Effects 0.000 description 10
- 230000004048 modification Effects 0.000 description 10
- 238000012986 modification Methods 0.000 description 10
- 238000012360 testing method Methods 0.000 description 10
- 238000011144 upstream manufacturing Methods 0.000 description 10
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 9
- 102100038950 Proprotein convertase subtilisin/kexin type 7 Human genes 0.000 description 9
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 9
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 9
- 239000004473 Threonine Substances 0.000 description 9
- 230000003247 decreasing effect Effects 0.000 description 9
- 235000019419 proteases Nutrition 0.000 description 9
- 108010089996 B-domain-deleted factor VIII Proteins 0.000 description 8
- 102000015081 Blood Coagulation Factors Human genes 0.000 description 8
- 108010039209 Blood Coagulation Factors Proteins 0.000 description 8
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 8
- 239000003114 blood coagulation factor Substances 0.000 description 8
- 201000010099 disease Diseases 0.000 description 8
- 108020004999 messenger RNA Proteins 0.000 description 8
- 230000037361 pathway Effects 0.000 description 8
- 230000002829 reductive effect Effects 0.000 description 8
- 108010093297 tetrapeptide carbamate Proteins 0.000 description 8
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 7
- 101710180647 Proprotein convertase subtilisin/kexin type 7 Proteins 0.000 description 7
- 239000003795 chemical substances by application Substances 0.000 description 7
- 239000012636 effector Substances 0.000 description 7
- 150000002500 ions Chemical class 0.000 description 7
- 230000000670 limiting effect Effects 0.000 description 7
- 230000036961 partial effect Effects 0.000 description 7
- 230000001105 regulatory effect Effects 0.000 description 7
- 230000010076 replication Effects 0.000 description 7
- 239000003981 vehicle Substances 0.000 description 7
- 108010014173 Factor X Proteins 0.000 description 6
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 6
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 6
- 108700026244 Open Reading Frames Proteins 0.000 description 6
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 6
- 241000700605 Viruses Species 0.000 description 6
- 230000001154 acute effect Effects 0.000 description 6
- 239000002299 complementary DNA Substances 0.000 description 6
- 239000000539 dimer Substances 0.000 description 6
- 229940012426 factor x Drugs 0.000 description 6
- 239000000833 heterodimer Substances 0.000 description 6
- 230000001939 inductive effect Effects 0.000 description 6
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 6
- 229960000310 isoleucine Drugs 0.000 description 6
- 230000022532 regulation of transcription, DNA-dependent Effects 0.000 description 6
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 6
- 241000894007 species Species 0.000 description 6
- 239000004474 valine Substances 0.000 description 6
- 235000014393 valine Nutrition 0.000 description 6
- 102100022641 Coagulation factor IX Human genes 0.000 description 5
- 108010073385 Fibrin Proteins 0.000 description 5
- 102000009123 Fibrin Human genes 0.000 description 5
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 description 5
- 108010091135 Immunoglobulin Fc Fragments Proteins 0.000 description 5
- 102000018071 Immunoglobulin Fc Fragments Human genes 0.000 description 5
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 5
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 5
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 5
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 5
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 5
- 241000699666 Mus <mouse, genus> Species 0.000 description 5
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 5
- 230000008859 change Effects 0.000 description 5
- 238000010367 cloning Methods 0.000 description 5
- 239000003623 enhancer Substances 0.000 description 5
- 230000002255 enzymatic effect Effects 0.000 description 5
- 229950003499 fibrin Drugs 0.000 description 5
- 239000000499 gel Substances 0.000 description 5
- 229930195712 glutamate Natural products 0.000 description 5
- 230000013595 glycosylation Effects 0.000 description 5
- 238000006206 glycosylation reaction Methods 0.000 description 5
- 238000000338 in vitro Methods 0.000 description 5
- 230000002401 inhibitory effect Effects 0.000 description 5
- 229930182817 methionine Natural products 0.000 description 5
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 5
- 229920000642 polymer Polymers 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- 238000013169 thromboelastometry Methods 0.000 description 5
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 5
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 4
- 241000701022 Cytomegalovirus Species 0.000 description 4
- 108010076282 Factor IX Proteins 0.000 description 4
- 108010087819 Fc receptors Proteins 0.000 description 4
- 102000009109 Fc receptors Human genes 0.000 description 4
- 241000282412 Homo Species 0.000 description 4
- 101001098529 Homo sapiens Proteinase-activated receptor 1 Proteins 0.000 description 4
- 101000713169 Homo sapiens Solute carrier family 52, riboflavin transporter, member 2 Proteins 0.000 description 4
- 229920001612 Hydroxyethyl starch Polymers 0.000 description 4
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 4
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 4
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 4
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 4
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 4
- 230000004988 N-glycosylation Effects 0.000 description 4
- 239000002202 Polyethylene glycol Substances 0.000 description 4
- 108010094028 Prothrombin Proteins 0.000 description 4
- 102100027378 Prothrombin Human genes 0.000 description 4
- 102100036862 Solute carrier family 52, riboflavin transporter, member 2 Human genes 0.000 description 4
- 238000007792 addition Methods 0.000 description 4
- 235000009582 asparagine Nutrition 0.000 description 4
- 229960001230 asparagine Drugs 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- 210000004899 c-terminal region Anatomy 0.000 description 4
- 239000010432 diamond Substances 0.000 description 4
- 210000000981 epithelium Anatomy 0.000 description 4
- 210000003527 eukaryotic cell Anatomy 0.000 description 4
- 239000013604 expression vector Substances 0.000 description 4
- 229960004222 factor ix Drugs 0.000 description 4
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 4
- 235000004554 glutamine Nutrition 0.000 description 4
- 208000031169 hemorrhagic disease Diseases 0.000 description 4
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 4
- 239000001257 hydrogen Substances 0.000 description 4
- 229910052739 hydrogen Inorganic materials 0.000 description 4
- 229940050526 hydroxyethylstarch Drugs 0.000 description 4
- 230000005847 immunogenicity Effects 0.000 description 4
- 210000004185 liver Anatomy 0.000 description 4
- 150000003904 phospholipids Chemical class 0.000 description 4
- 210000002381 plasma Anatomy 0.000 description 4
- 229920001223 polyethylene glycol Polymers 0.000 description 4
- 230000006337 proteolytic cleavage Effects 0.000 description 4
- 229940039716 prothrombin Drugs 0.000 description 4
- 230000009467 reduction Effects 0.000 description 4
- 239000004055 small Interfering RNA Substances 0.000 description 4
- 125000006850 spacer group Chemical group 0.000 description 4
- 238000010186 staining Methods 0.000 description 4
- 230000004083 survival effect Effects 0.000 description 4
- 230000032258 transport Effects 0.000 description 4
- 125000001433 C-terminal amino-acid group Chemical group 0.000 description 3
- 108020004705 Codon Proteins 0.000 description 3
- 102000053602 DNA Human genes 0.000 description 3
- 108010071289 Factor XIII Proteins 0.000 description 3
- 108010049003 Fibrinogen Proteins 0.000 description 3
- 102000008946 Fibrinogen Human genes 0.000 description 3
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 3
- 101100156611 Homo sapiens VWF gene Proteins 0.000 description 3
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 3
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 3
- 108091092195 Intron Proteins 0.000 description 3
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 3
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 3
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 3
- 239000004472 Lysine Substances 0.000 description 3
- 125000000729 N-terminal amino-acid group Chemical group 0.000 description 3
- 241000283973 Oryctolagus cuniculus Species 0.000 description 3
- 125000000637 arginyl group Chemical group N[C@@H](CCCNC(N)=N)C(=O)* 0.000 description 3
- 235000003704 aspartic acid Nutrition 0.000 description 3
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 3
- 108090001015 cancer procoagulant Proteins 0.000 description 3
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 238000010586 diagram Methods 0.000 description 3
- 229910003460 diamond Inorganic materials 0.000 description 3
- 201000007219 factor XI deficiency Diseases 0.000 description 3
- 229940012952 fibrinogen Drugs 0.000 description 3
- 235000013922 glutamic acid Nutrition 0.000 description 3
- 239000004220 glutamic acid Substances 0.000 description 3
- 208000009429 hemophilia B Diseases 0.000 description 3
- 230000023597 hemostasis Effects 0.000 description 3
- 239000000710 homodimer Substances 0.000 description 3
- 230000001976 improved effect Effects 0.000 description 3
- 238000010348 incorporation Methods 0.000 description 3
- 230000001404 mediated effect Effects 0.000 description 3
- 108010068617 neonatal Fc receptor Proteins 0.000 description 3
- 230000008488 polyadenylation Effects 0.000 description 3
- 230000002028 premature Effects 0.000 description 3
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 3
- 230000017854 proteolysis Effects 0.000 description 3
- 210000002966 serum Anatomy 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- 230000005030 transcription termination Effects 0.000 description 3
- 238000002054 transplantation Methods 0.000 description 3
- 241001430294 unidentified retrovirus Species 0.000 description 3
- 239000013603 viral vector Substances 0.000 description 3
- 230000003612 virological effect Effects 0.000 description 3
- 102000007469 Actins Human genes 0.000 description 2
- 108010085238 Actins Proteins 0.000 description 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
- 241000282465 Canis Species 0.000 description 2
- 241000700199 Cavia porcellus Species 0.000 description 2
- 108010035563 Chloramphenicol O-acetyltransferase Proteins 0.000 description 2
- 208000017667 Chronic Disease Diseases 0.000 description 2
- 102000008186 Collagen Human genes 0.000 description 2
- 108010035532 Collagen Proteins 0.000 description 2
- 108010014172 Factor V Proteins 0.000 description 2
- 201000007176 Factor XII Deficiency Diseases 0.000 description 2
- 239000004606 Fillers/Extenders Substances 0.000 description 2
- 102100035233 Furin Human genes 0.000 description 2
- 108700039691 Genetic Promoter Regions Proteins 0.000 description 2
- 108010043121 Green Fluorescent Proteins Proteins 0.000 description 2
- 102000004144 Green Fluorescent Proteins Human genes 0.000 description 2
- 206010062713 Haemorrhagic diathesis Diseases 0.000 description 2
- 208000024659 Hemostatic disease Diseases 0.000 description 2
- 101001022148 Homo sapiens Furin Proteins 0.000 description 2
- 101001072081 Homo sapiens Proprotein convertase subtilisin/kexin type 5 Proteins 0.000 description 2
- 101001098833 Homo sapiens Proprotein convertase subtilisin/kexin type 6 Proteins 0.000 description 2
- 241000725303 Human immunodeficiency virus Species 0.000 description 2
- 102000018251 Hypoxanthine Phosphoribosyltransferase Human genes 0.000 description 2
- 108010091358 Hypoxanthine Phosphoribosyltransferase Proteins 0.000 description 2
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 2
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 2
- 241000282553 Macaca Species 0.000 description 2
- 241000829100 Macaca mulatta polyomavirus 1 Species 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- 102100037732 Neuroendocrine convertase 2 Human genes 0.000 description 2
- 238000012408 PCR amplification Methods 0.000 description 2
- 241000282577 Pan troglodytes Species 0.000 description 2
- 108091093037 Peptide nucleic acid Proteins 0.000 description 2
- 102000010780 Platelet-Derived Growth Factor Human genes 0.000 description 2
- 108010038512 Platelet-Derived Growth Factor Proteins 0.000 description 2
- 102000006437 Proprotein Convertases Human genes 0.000 description 2
- 108010044159 Proprotein Convertases Proteins 0.000 description 2
- 102100036371 Proprotein convertase subtilisin/kexin type 4 Human genes 0.000 description 2
- 102100038946 Proprotein convertase subtilisin/kexin type 6 Human genes 0.000 description 2
- 241000700159 Rattus Species 0.000 description 2
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 2
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 2
- 241000283984 Rodentia Species 0.000 description 2
- 241000714474 Rous sarcoma virus Species 0.000 description 2
- 108091027967 Small hairpin RNA Proteins 0.000 description 2
- 108020004459 Small interfering RNA Proteins 0.000 description 2
- 108091081024 Start codon Proteins 0.000 description 2
- 208000000392 Thrombasthenia Diseases 0.000 description 2
- 102000003978 Tissue Plasminogen Activator Human genes 0.000 description 2
- 108090000373 Tissue Plasminogen Activator Proteins 0.000 description 2
- 108020004566 Transfer RNA Proteins 0.000 description 2
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 2
- 230000005856 abnormality Effects 0.000 description 2
- 230000003321 amplification Effects 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 230000008499 blood brain barrier function Effects 0.000 description 2
- 210000001218 blood-brain barrier Anatomy 0.000 description 2
- 210000004556 brain Anatomy 0.000 description 2
- 239000006227 byproduct Substances 0.000 description 2
- 239000011575 calcium Substances 0.000 description 2
- 229910052791 calcium Inorganic materials 0.000 description 2
- 230000015556 catabolic process Effects 0.000 description 2
- 229910052801 chlorine Inorganic materials 0.000 description 2
- 229920001436 collagen Polymers 0.000 description 2
- 210000001072 colon Anatomy 0.000 description 2
- 230000004540 complement-dependent cytotoxicity Effects 0.000 description 2
- 208000011664 congenital factor XI deficiency Diseases 0.000 description 2
- 230000021615 conjugation Effects 0.000 description 2
- 238000010276 construction Methods 0.000 description 2
- 230000009089 cytolysis Effects 0.000 description 2
- 230000007547 defect Effects 0.000 description 2
- 230000007812 deficiency Effects 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 230000029087 digestion Effects 0.000 description 2
- 230000007717 exclusion Effects 0.000 description 2
- 229940012444 factor xiii Drugs 0.000 description 2
- 230000002068 genetic effect Effects 0.000 description 2
- 239000005090 green fluorescent protein Substances 0.000 description 2
- 125000001165 hydrophobic group Chemical group 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 230000006698 induction Effects 0.000 description 2
- 238000005342 ion exchange Methods 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 210000004379 membrane Anatomy 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 229910021645 metal ion Inorganic materials 0.000 description 2
- 230000009871 nonspecific binding Effects 0.000 description 2
- 238000003199 nucleic acid amplification method Methods 0.000 description 2
- 230000003647 oxidation Effects 0.000 description 2
- 238000007254 oxidation reaction Methods 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 238000011321 prophylaxis Methods 0.000 description 2
- 230000004952 protein activity Effects 0.000 description 2
- 230000002797 proteolythic effect Effects 0.000 description 2
- 230000002685 pulmonary effect Effects 0.000 description 2
- 238000004064 recycling Methods 0.000 description 2
- 239000000523 sample Substances 0.000 description 2
- 230000003248 secreting effect Effects 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 230000009870 specific binding Effects 0.000 description 2
- 210000000952 spleen Anatomy 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- XOAAWQZATWQOTB-UHFFFAOYSA-N taurine Chemical compound NCCS(O)(=O)=O XOAAWQZATWQOTB-UHFFFAOYSA-N 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 125000003396 thiol group Chemical group [H]S* 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 229960000187 tissue plasminogen activator Drugs 0.000 description 2
- 230000014621 translational initiation Effects 0.000 description 2
- 241000701161 unidentified adenovirus Species 0.000 description 2
- DIGQNXIGRZPYDK-WKSCXVIASA-N (2R)-6-amino-2-[[2-[[(2S)-2-[[2-[[(2R)-2-[[(2S)-2-[[(2R,3S)-2-[[2-[[(2S)-2-[[2-[[(2S)-2-[[(2S)-2-[[(2R)-2-[[(2S,3S)-2-[[(2R)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[2-[[(2S)-2-[[(2R)-2-[[2-[[2-[[2-[(2-amino-1-hydroxyethylidene)amino]-3-carboxy-1-hydroxypropylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1-hydroxyethylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1,3-dihydroxypropylidene]amino]-1-hydroxyethylidene]amino]-1-hydroxypropylidene]amino]-1,3-dihydroxypropylidene]amino]-1,3-dihydroxypropylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1,3-dihydroxybutylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1-hydroxypropylidene]amino]-1,3-dihydroxypropylidene]amino]-1-hydroxyethylidene]amino]-1,5-dihydroxy-5-iminopentylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1,3-dihydroxybutylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1,3-dihydroxypropylidene]amino]-1-hydroxyethylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1-hydroxyethylidene]amino]hexanoic acid Chemical compound C[C@@H]([C@@H](C(=N[C@@H](CS)C(=N[C@@H](C)C(=N[C@@H](CO)C(=NCC(=N[C@@H](CCC(=N)O)C(=NC(CS)C(=N[C@H]([C@H](C)O)C(=N[C@H](CS)C(=N[C@H](CO)C(=NCC(=N[C@H](CS)C(=NCC(=N[C@H](CCCCN)C(=O)O)O)O)O)O)O)O)O)O)O)O)O)O)O)N=C([C@H](CS)N=C([C@H](CO)N=C([C@H](CO)N=C([C@H](C)N=C(CN=C([C@H](CO)N=C([C@H](CS)N=C(CN=C(C(CS)N=C(C(CC(=O)O)N=C(CN)O)O)O)O)O)O)O)O)O)O)O)O DIGQNXIGRZPYDK-WKSCXVIASA-N 0.000 description 1
- PGOHTUIFYSHAQG-LJSDBVFPSA-N (2S)-6-amino-2-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-4-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-5-amino-2-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S,3R)-2-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S,3R)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-5-amino-2-[[(2S)-1-[(2S,3R)-2-[[(2S)-2-[[(2S)-2-[[(2R)-2-[[(2S)-2-[[(2S)-2-[[2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-1-[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-amino-4-methylsulfanylbutanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-5-carbamimidamidopentanoyl]amino]propanoyl]pyrrolidine-2-carbonyl]amino]-3-methylbutanoyl]amino]-4-methylpentanoyl]amino]-4-methylpentanoyl]amino]acetyl]amino]-3-hydroxypropanoyl]amino]-4-methylpentanoyl]amino]-3-sulfanylpropanoyl]amino]-4-methylsulfanylbutanoyl]amino]-5-carbamimidamidopentanoyl]amino]-3-hydroxybutanoyl]pyrrolidine-2-carbonyl]amino]-5-oxopentanoyl]amino]-3-hydroxypropanoyl]amino]-3-hydroxypropanoyl]amino]-3-(1H-imidazol-5-yl)propanoyl]amino]-4-methylpentanoyl]amino]-3-hydroxybutanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-5-carbamimidamidopentanoyl]amino]-5-oxopentanoyl]amino]-3-hydroxybutanoyl]amino]-3-hydroxypropanoyl]amino]-3-carboxypropanoyl]amino]-3-hydroxypropanoyl]amino]-5-oxopentanoyl]amino]-5-oxopentanoyl]amino]-3-phenylpropanoyl]amino]-5-carbamimidamidopentanoyl]amino]-3-methylbutanoyl]amino]-4-methylpentanoyl]amino]-4-oxobutanoyl]amino]-5-carbamimidamidopentanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-4-carboxybutanoyl]amino]-5-oxopentanoyl]amino]hexanoic acid Chemical compound CSCC[C@H](N)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N1CCC[C@H]1C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](Cc1cnc[nH]1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCCN)C(O)=O PGOHTUIFYSHAQG-LJSDBVFPSA-N 0.000 description 1
- FDKWRPBBCBCIGA-REOHCLBHSA-N (2r)-2-azaniumyl-3-$l^{1}-selanylpropanoate Chemical compound [Se]C[C@H](N)C(O)=O FDKWRPBBCBCIGA-REOHCLBHSA-N 0.000 description 1
- CBCKQZAAMUWICA-UHFFFAOYSA-N 1,4-phenylenediamine Chemical compound NC1=CC=C(N)C=C1 CBCKQZAAMUWICA-UHFFFAOYSA-N 0.000 description 1
- NFGXHKASABOEEW-UHFFFAOYSA-N 1-methylethyl 11-methoxy-3,7,11-trimethyl-2,4-dodecadienoate Chemical compound COC(C)(C)CCCC(C)CC=CC(C)=CC(=O)OC(C)C NFGXHKASABOEEW-UHFFFAOYSA-N 0.000 description 1
- BFSVOASYOCHEOV-UHFFFAOYSA-N 2-diethylaminoethanol Chemical compound CCN(CC)CCO BFSVOASYOCHEOV-UHFFFAOYSA-N 0.000 description 1
- 101150096316 5 gene Proteins 0.000 description 1
- 101710169336 5'-deoxyadenosine deaminase Proteins 0.000 description 1
- FVFVNNKYKYZTJU-UHFFFAOYSA-N 6-chloro-1,3,5-triazine-2,4-diamine Chemical group NC1=NC(N)=NC(Cl)=N1 FVFVNNKYKYZTJU-UHFFFAOYSA-N 0.000 description 1
- 102000055025 Adenosine deaminases Human genes 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- 108700028369 Alleles Proteins 0.000 description 1
- 208000037157 Azotemia Diseases 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 208000001593 Bernard-Soulier syndrome Diseases 0.000 description 1
- 101000889335 Bombyx mori Trypsin inhibitor Proteins 0.000 description 1
- 108010078791 Carrier Proteins Proteins 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- 102100023804 Coagulation factor VII Human genes 0.000 description 1
- 102000000989 Complement System Proteins Human genes 0.000 description 1
- 108010069112 Complement System Proteins Proteins 0.000 description 1
- 208000028702 Congenital thrombocyte disease Diseases 0.000 description 1
- 239000003154 D dimer Substances 0.000 description 1
- FDKWRPBBCBCIGA-UWTATZPHSA-N D-Selenocysteine Natural products [Se]C[C@@H](N)C(O)=O FDKWRPBBCBCIGA-UWTATZPHSA-N 0.000 description 1
- SHZGCJCMOBCMKK-UHFFFAOYSA-N D-mannomethylose Natural products CC1OC(O)C(O)C(O)C1O SHZGCJCMOBCMKK-UHFFFAOYSA-N 0.000 description 1
- 241000271032 Daboia russelii Species 0.000 description 1
- 241000702421 Dependoparvovirus Species 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- BWGNESOTFCXPMA-UHFFFAOYSA-N Dihydrogen disulfide Chemical compound SS BWGNESOTFCXPMA-UHFFFAOYSA-N 0.000 description 1
- 108010016626 Dipeptides Proteins 0.000 description 1
- 102000005593 Endopeptidases Human genes 0.000 description 1
- 108010059378 Endopeptidases Proteins 0.000 description 1
- YQYJSBFKSSDGFO-UHFFFAOYSA-N Epihygromycin Natural products OC1C(O)C(C(=O)C)OC1OC(C(=C1)O)=CC=C1C=C(C)C(=O)NC1C(O)C(O)C2OCOC2C1O YQYJSBFKSSDGFO-UHFFFAOYSA-N 0.000 description 1
- 108010079356 FIIa Proteins 0.000 description 1
- 206010016077 Factor IX deficiency Diseases 0.000 description 1
- 108010023321 Factor VII Proteins 0.000 description 1
- PNNNRSAQSRJVSB-SLPGGIOYSA-N Fucose Natural products C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)C=O PNNNRSAQSRJVSB-SLPGGIOYSA-N 0.000 description 1
- 229930182566 Gentamicin Natural products 0.000 description 1
- CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 description 1
- 208000013607 Glanzmann thrombasthenia Diseases 0.000 description 1
- 208000032371 Glanzmann thrombasthenia 1 Diseases 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 102000002812 Heat-Shock Proteins Human genes 0.000 description 1
- 108010004889 Heat-Shock Proteins Proteins 0.000 description 1
- 208000031220 Hemophilia Diseases 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- 206010019663 Hepatic failure Diseases 0.000 description 1
- 101001128694 Homo sapiens Neuroendocrine convertase 1 Proteins 0.000 description 1
- 101000601394 Homo sapiens Neuroendocrine convertase 2 Proteins 0.000 description 1
- 101001072067 Homo sapiens Proprotein convertase subtilisin/kexin type 4 Proteins 0.000 description 1
- 101000782195 Homo sapiens von Willebrand factor Proteins 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- 108010073807 IgG Receptors Proteins 0.000 description 1
- 102000009490 IgG Receptors Human genes 0.000 description 1
- 102100026214 Indian hedgehog protein Human genes 0.000 description 1
- 102000014150 Interferons Human genes 0.000 description 1
- 108010050904 Interferons Proteins 0.000 description 1
- 102000015696 Interleukins Human genes 0.000 description 1
- 108010063738 Interleukins Proteins 0.000 description 1
- 108020004684 Internal Ribosome Entry Sites Proteins 0.000 description 1
- 101710172072 Kexin Proteins 0.000 description 1
- AHLPHDHHMVZTML-BYPYZUCNSA-N L-Ornithine Chemical compound NCCC[C@H](N)C(O)=O AHLPHDHHMVZTML-BYPYZUCNSA-N 0.000 description 1
- 150000008575 L-amino acids Chemical class 0.000 description 1
- SHZGCJCMOBCMKK-DHVFOXMCSA-N L-fucopyranose Chemical compound C[C@@H]1OC(O)[C@@H](O)[C@H](O)[C@@H]1O SHZGCJCMOBCMKK-DHVFOXMCSA-N 0.000 description 1
- ZFOMKMMPBOQKMC-KXUCPTDWSA-N L-pyrrolysine Chemical compound C[C@@H]1CC=N[C@H]1C(=O)NCCCC[C@H]([NH3+])C([O-])=O ZFOMKMMPBOQKMC-KXUCPTDWSA-N 0.000 description 1
- 229910008403 Li-V Inorganic materials 0.000 description 1
- 229910007058 Li—V Inorganic materials 0.000 description 1
- 108060001084 Luciferase Proteins 0.000 description 1
- 239000005089 Luciferase Substances 0.000 description 1
- 102000003792 Metallothionein Human genes 0.000 description 1
- 108090000157 Metallothionein Proteins 0.000 description 1
- 102100032132 Neuroendocrine convertase 1 Human genes 0.000 description 1
- 108010038807 Oligopeptides Proteins 0.000 description 1
- 102000015636 Oligopeptides Human genes 0.000 description 1
- AHLPHDHHMVZTML-UHFFFAOYSA-N Orn-delta-NH2 Natural products NCCCC(N)C(O)=O AHLPHDHHMVZTML-UHFFFAOYSA-N 0.000 description 1
- UTJLXEIPEHZYQJ-UHFFFAOYSA-N Ornithine Natural products OC(=O)C(C)CCCN UTJLXEIPEHZYQJ-UHFFFAOYSA-N 0.000 description 1
- 241000282320 Panthera leo Species 0.000 description 1
- 108090000526 Papain Proteins 0.000 description 1
- 241001631646 Papillomaviridae Species 0.000 description 1
- 206010057249 Phagocytosis Diseases 0.000 description 1
- 241000709664 Picornaviridae Species 0.000 description 1
- 208000013544 Platelet disease Diseases 0.000 description 1
- XBDQKXXYIPTUBI-UHFFFAOYSA-N Propionic acid Chemical compound CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 1
- 108090000545 Proprotein Convertase 2 Proteins 0.000 description 1
- 101710180646 Proprotein convertase subtilisin/kexin type 4 Proteins 0.000 description 1
- 101710180648 Proprotein convertase subtilisin/kexin type 5 Proteins 0.000 description 1
- 101800004937 Protein C Proteins 0.000 description 1
- 102000017975 Protein C Human genes 0.000 description 1
- 108010001267 Protein Subunits Proteins 0.000 description 1
- 102000002067 Protein Subunits Human genes 0.000 description 1
- 102000013009 Pyruvate Kinase Human genes 0.000 description 1
- 108020005115 Pyruvate Kinase Proteins 0.000 description 1
- 238000001069 Raman spectroscopy Methods 0.000 description 1
- 101000913100 Rattus norvegicus IgG receptor FcRn large subunit p51 Proteins 0.000 description 1
- 108700005075 Regulator Genes Proteins 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 101800001700 Saposin-D Proteins 0.000 description 1
- 238000012300 Sequence Analysis Methods 0.000 description 1
- 108010071390 Serum Albumin Proteins 0.000 description 1
- 102000007562 Serum Albumin Human genes 0.000 description 1
- 102000005686 Serum Globulins Human genes 0.000 description 1
- 108010045362 Serum Globulins Proteins 0.000 description 1
- 241000700584 Simplexvirus Species 0.000 description 1
- 108020004682 Single-Stranded DNA Proteins 0.000 description 1
- 108090000787 Subtilisin Proteins 0.000 description 1
- 108700026226 TATA Box Proteins 0.000 description 1
- 108020005038 Terminator Codon Proteins 0.000 description 1
- 108010000499 Thromboplastin Proteins 0.000 description 1
- 102000002262 Thromboplastin Human genes 0.000 description 1
- 102000006601 Thymidine Kinase Human genes 0.000 description 1
- 108020004440 Thymidine kinase Proteins 0.000 description 1
- 108090000992 Transferases Proteins 0.000 description 1
- 241000700618 Vaccinia virus Species 0.000 description 1
- 208000027276 Von Willebrand disease Diseases 0.000 description 1
- 230000021736 acetylation Effects 0.000 description 1
- 238000006640 acetylation reaction Methods 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 239000008186 active pharmaceutical agent Substances 0.000 description 1
- 230000009056 active transport Effects 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 125000003295 alanine group Chemical group N[C@@H](C)C(=O)* 0.000 description 1
- 230000009435 amidation Effects 0.000 description 1
- 238000007112 amidation reaction Methods 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 229960000723 ampicillin Drugs 0.000 description 1
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 1
- 238000001286 analytical centrifugation Methods 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 229930002877 anthocyanin Natural products 0.000 description 1
- 235000010208 anthocyanin Nutrition 0.000 description 1
- 239000004410 anthocyanin Substances 0.000 description 1
- 150000004636 anthocyanins Chemical class 0.000 description 1
- 230000003466 anti-cipated effect Effects 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 229940030225 antihemorrhagics Drugs 0.000 description 1
- 238000000149 argon plasma sintering Methods 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 210000004082 barrier epithelial cell Anatomy 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- GINJFDRNADDBIN-FXQIFTODSA-N bilanafos Chemical compound OC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](N)CCP(C)(O)=O GINJFDRNADDBIN-FXQIFTODSA-N 0.000 description 1
- 210000003445 biliary tract Anatomy 0.000 description 1
- 229920001222 biopolymer Polymers 0.000 description 1
- 230000002051 biphasic effect Effects 0.000 description 1
- 239000002981 blocking agent Substances 0.000 description 1
- 208000014759 blood platelet disease Diseases 0.000 description 1
- 108010006025 bovine growth hormone Proteins 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 238000005251 capillar electrophoresis Methods 0.000 description 1
- 239000005018 casein Substances 0.000 description 1
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 1
- 235000021240 caseins Nutrition 0.000 description 1
- 230000032823 cell division Effects 0.000 description 1
- 230000007910 cell fusion Effects 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 210000000349 chromosome Anatomy 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 238000002983 circular dichroism Methods 0.000 description 1
- 239000013599 cloning vector Substances 0.000 description 1
- 229940105778 coagulation factor viii Drugs 0.000 description 1
- 208000014763 coagulation protein disease Diseases 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 238000004590 computer program Methods 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 238000002447 crystallographic data Methods 0.000 description 1
- 210000004748 cultured cell Anatomy 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 238000001212 derivatisation Methods 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000002059 diagnostic imaging Methods 0.000 description 1
- 238000000113 differential scanning calorimetry Methods 0.000 description 1
- 230000003467 diminishing effect Effects 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 238000004520 electroporation Methods 0.000 description 1
- 229940066758 endopeptidases Drugs 0.000 description 1
- 210000003038 endothelium Anatomy 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 230000004890 epithelial barrier function Effects 0.000 description 1
- 238000011067 equilibration Methods 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 210000003722 extracellular fluid Anatomy 0.000 description 1
- 230000006624 extrinsic pathway Effects 0.000 description 1
- 108010091897 factor V Leiden Proteins 0.000 description 1
- 201000007386 factor VII deficiency Diseases 0.000 description 1
- 108700019309 factor VIII-Fc fusion Proteins 0.000 description 1
- 229940012413 factor vii Drugs 0.000 description 1
- 108010052295 fibrin fragment D Proteins 0.000 description 1
- 230000020764 fibrinolysis Effects 0.000 description 1
- 229910052731 fluorine Inorganic materials 0.000 description 1
- 230000037433 frameshift Effects 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 229910052736 halogen Inorganic materials 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 239000002874 hemostatic agent Substances 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 230000002363 herbicidal effect Effects 0.000 description 1
- 239000004009 herbicide Substances 0.000 description 1
- 229940084986 human chorionic gonadotropin Drugs 0.000 description 1
- 229960000900 human factor viii Drugs 0.000 description 1
- 210000004408 hybridoma Anatomy 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 102000006495 integrins Human genes 0.000 description 1
- 108010044426 integrins Proteins 0.000 description 1
- 238000009830 intercalation Methods 0.000 description 1
- 230000002687 intercalation Effects 0.000 description 1
- 229940047124 interferons Drugs 0.000 description 1
- 229940047122 interleukins Drugs 0.000 description 1
- 210000004347 intestinal mucosa Anatomy 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 230000010189 intracellular transport Effects 0.000 description 1
- 229940065638 intron a Drugs 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 229960000318 kanamycin Drugs 0.000 description 1
- 229930027917 kanamycin Natural products 0.000 description 1
- SBUJHOSQTJFQJX-NOAMYHISSA-N kanamycin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N SBUJHOSQTJFQJX-NOAMYHISSA-N 0.000 description 1
- 229930182823 kanamycin A Natural products 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 238000001638 lipofection Methods 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 208000007903 liver failure Diseases 0.000 description 1
- 231100000835 liver failure Toxicity 0.000 description 1
- 230000004807 localization Effects 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 210000002751 lymph Anatomy 0.000 description 1
- 125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 1
- 210000003712 lysosome Anatomy 0.000 description 1
- 230000001868 lysosomic effect Effects 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 210000003593 megakaryocyte Anatomy 0.000 description 1
- 230000011987 methylation Effects 0.000 description 1
- 238000007069 methylation reaction Methods 0.000 description 1
- 238000000520 microinjection Methods 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 238000002703 mutagenesis Methods 0.000 description 1
- 231100000350 mutagenesis Toxicity 0.000 description 1
- 210000002850 nasal mucosa Anatomy 0.000 description 1
- 108091027963 non-coding RNA Proteins 0.000 description 1
- 102000042567 non-coding RNA Human genes 0.000 description 1
- 229960003104 ornithine Drugs 0.000 description 1
- 229940055729 papain Drugs 0.000 description 1
- 235000019834 papain Nutrition 0.000 description 1
- 230000006320 pegylation Effects 0.000 description 1
- 230000008782 phagocytosis Effects 0.000 description 1
- 230000003285 pharmacodynamic effect Effects 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- 230000008884 pinocytosis Effects 0.000 description 1
- 210000002826 placenta Anatomy 0.000 description 1
- 230000036470 plasma concentration Effects 0.000 description 1
- 238000003752 polymerase chain reaction Methods 0.000 description 1
- 230000004481 post-translational protein modification Effects 0.000 description 1
- 230000001124 posttranscriptional effect Effects 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 230000019525 primary metabolic process Effects 0.000 description 1
- 230000002947 procoagulating effect Effects 0.000 description 1
- 125000001500 prolyl group Chemical group [H]N1C([H])(C(=O)[*])C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- 230000000644 propagated effect Effects 0.000 description 1
- 229960000856 protein c Drugs 0.000 description 1
- 230000004850 protein–protein interaction Effects 0.000 description 1
- 230000005180 public health Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 230000003252 repetitive effect Effects 0.000 description 1
- 230000003362 replicative effect Effects 0.000 description 1
- 238000002271 resection Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 210000003935 rough endoplasmic reticulum Anatomy 0.000 description 1
- 229940055619 selenocysteine Drugs 0.000 description 1
- ZKZBPNGNEQAJSX-UHFFFAOYSA-N selenocysteine Natural products [SeH]CC(N)C(O)=O ZKZBPNGNEQAJSX-UHFFFAOYSA-N 0.000 description 1
- 235000016491 selenocysteine Nutrition 0.000 description 1
- 125000003607 serino group Chemical group [H]N([H])[C@]([H])(C(=O)[*])C(O[H])([H])[H] 0.000 description 1
- 238000002741 site-directed mutagenesis Methods 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 238000004611 spectroscopical analysis Methods 0.000 description 1
- 238000011476 stem cell transplantation Methods 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 229940124530 sulfonamide Drugs 0.000 description 1
- 150000003456 sulfonamides Chemical class 0.000 description 1
- 229960003080 taurine Drugs 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 230000002103 transcriptional effect Effects 0.000 description 1
- 238000010361 transduction Methods 0.000 description 1
- 230000026683 transduction Effects 0.000 description 1
- 238000001890 transfection Methods 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 230000001131 transforming effect Effects 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 239000013638 trimer Substances 0.000 description 1
- 241000701447 unidentified baculovirus Species 0.000 description 1
- 241001529453 unidentified herpesvirus Species 0.000 description 1
- 208000009852 uremia Diseases 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 208000012908 vascular hemostatic disease Diseases 0.000 description 1
- 210000005166 vasculature Anatomy 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 239000002821 viper venom Substances 0.000 description 1
- 208000012137 von Willebrand disease (hereditary or acquired) Diseases 0.000 description 1
- 210000004269 weibel-palade body Anatomy 0.000 description 1
- 239000002023 wood Substances 0.000 description 1
- 238000002424 x-ray crystallography Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/745—Blood coagulation or fibrinolysis factors
- C07K14/755—Factors VIII, e.g. factor VIII C (AHF), factor VIII Ag (VWF)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/36—Blood coagulation or fibrinolysis factors
- A61K38/37—Factors VIII
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Molecular Biology (AREA)
- Hematology (AREA)
- Immunology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Epidemiology (AREA)
- Toxicology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Physical Education & Sports Medicine (AREA)
- Diabetes (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201461926226P | 2014-01-10 | 2014-01-10 | |
| US61/926,226 | 2014-01-10 | ||
| US201461988104P | 2014-05-02 | 2014-05-02 | |
| US61/988,104 | 2014-05-02 | ||
| PCT/US2015/010738 WO2015106052A1 (en) | 2014-01-10 | 2015-01-09 | Factor viii chimeric proteins and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2935954A1 true CA2935954A1 (en) | 2015-07-16 |
Family
ID=53524349
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2935954A Pending CA2935954A1 (en) | 2014-01-10 | 2015-01-09 | Factor viii chimeric proteins and uses thereof |
Country Status (30)
| Country | Link |
|---|---|
| US (3) | US11192936B2 (enExample) |
| EP (3) | EP4176894B1 (enExample) |
| JP (5) | JP6749836B2 (enExample) |
| KR (1) | KR102409250B1 (enExample) |
| CN (6) | CN116731201A (enExample) |
| AU (3) | AU2015204646B2 (enExample) |
| BR (1) | BR112016015512B1 (enExample) |
| CA (1) | CA2935954A1 (enExample) |
| DK (2) | DK3091997T5 (enExample) |
| EA (1) | EA201691111A1 (enExample) |
| ES (2) | ES2927475T3 (enExample) |
| FI (2) | FI4176894T3 (enExample) |
| FR (1) | FR24C1052I1 (enExample) |
| HR (2) | HRP20240640T1 (enExample) |
| HU (3) | HUE059820T2 (enExample) |
| IL (2) | IL246476B (enExample) |
| LT (3) | LT3091997T (enExample) |
| MX (2) | MX389878B (enExample) |
| MY (2) | MY192481A (enExample) |
| NL (1) | NL301303I2 (enExample) |
| NO (1) | NO2024057I1 (enExample) |
| NZ (1) | NZ721544A (enExample) |
| PH (1) | PH12016501323B1 (enExample) |
| PL (2) | PL3091997T3 (enExample) |
| PT (2) | PT3091997T (enExample) |
| RS (2) | RS65533B1 (enExample) |
| SG (3) | SG10201913697UA (enExample) |
| SI (2) | SI3091997T1 (enExample) |
| UA (1) | UA120917C2 (enExample) |
| WO (1) | WO2015106052A1 (enExample) |
Families Citing this family (45)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2010091122A1 (en) * | 2009-02-03 | 2010-08-12 | Amunix, Inc. | Extended recombinant polypeptides and compositions comprising same |
| BR112012004094A2 (pt) | 2009-08-24 | 2016-03-08 | Amunix Operating Inc | composições de fator vii de coagulação e métodos para fazer e usar as mesmas |
| EA035323B1 (ru) * | 2012-01-12 | 2020-05-28 | Биовератив Терапьютикс Инк. | Полипептиды химерного фактора viii и их применение |
| LT2822577T (lt) | 2012-02-15 | 2019-03-25 | Bioverativ Therapeutics Inc. | Rekombinantiniai faktoriaus viii baltymai |
| HRP20221531T1 (hr) | 2012-02-15 | 2023-02-17 | Bioverativ Therapeutics Inc. | Pripravci faktora viii i postupci dobivanja i korištenja istih |
| US10138291B2 (en) | 2012-07-11 | 2018-11-27 | Bioverativ Therapeutics Inc. | Factor VIII complex with XTEN and von Willebrand Factor protein, and uses thereof |
| LT2956477T (lt) | 2013-02-15 | 2021-02-10 | Bioverativ Therapeutics Inc. | Optimizuotas faktoriaus viii genas |
| EA037906B1 (ru) | 2013-03-15 | 2021-06-04 | Биовератив Терапьютикс Инк. | Препараты полипептида фактора ix |
| WO2014210558A1 (en) * | 2013-06-28 | 2014-12-31 | Biogen Idec Ma Inc. | Thrombin cleavable linker with xten and its uses thereof |
| EP3033097B1 (en) | 2013-08-14 | 2021-03-10 | Bioverativ Therapeutics Inc. | Factor viii-xten fusions and uses thereof |
| DK3091997T5 (da) * | 2014-01-10 | 2024-10-14 | Bioverativ Therapeutics Inc | Kimære faktor viii-proteiner og anvendelser deraf |
| EP3160478A4 (en) | 2014-06-30 | 2018-05-16 | Bioverativ Therapeutics Inc. | Optimized factor ix gene |
| SG11201708755WA (en) * | 2015-05-22 | 2017-12-28 | Csl Behring Recombinant Facility Ag | Truncated von willebrand factor polypeptides for treating hemophilia |
| MX2018001497A (es) | 2015-08-03 | 2018-05-15 | Bioverativ Therapeutics Inc | Proteinas de fusion de factor ix y metodos para producirlas y usarlas. |
| WO2017050820A1 (en) * | 2015-09-22 | 2017-03-30 | Novo Nordisk A/S | Fviii fusion proteins |
| CN105567733B (zh) * | 2016-01-11 | 2019-04-23 | 佛山安普泽生物医药股份有限公司 | CHO细胞表达凝血酶-Fc融合蛋白的方法 |
| US10626186B2 (en) | 2016-01-26 | 2020-04-21 | Inserm (Institut National De La Sante Et De La Recherche Medicale) | Anti-VWF D'D3 single-domain antibodies and methods of use |
| PL3411478T3 (pl) | 2016-02-01 | 2022-10-03 | Bioverativ Therapeutics Inc. | Geny zoptymalizowanego czynnika VIII |
| WO2017197048A1 (en) * | 2016-05-11 | 2017-11-16 | Amunix Operating Inc. | Albumin binding conjugate compositions and methods of making and using same |
| JP6877469B2 (ja) | 2016-06-24 | 2021-05-26 | モガム・インスティテュート・フォー・バイオメディカル・リサーチＭｏｇａｍ Ｉｎｓｔｉｔｕｔｅ Ｆｏｒ Ｂｉｏｍｅｄｉｃａｌ Ｒｅｓｅａｒｃｈ | Ｆｖｉｉｉおよびｖｗｆ因子を含むキメラタンパク質、ならびにそれらの使用 |
| BR112019011198A2 (pt) | 2016-12-02 | 2019-12-17 | Bioverativ Therapeutics Inc | métodos de indução de tolerância imune a fatores de coagulação |
| WO2018102743A1 (en) | 2016-12-02 | 2018-06-07 | Bioverativ Therapeutics Inc. | Methods of treating hemophilic arthropathy using chimeric clotting factors |
| GB201707139D0 (en) | 2017-05-04 | 2017-06-21 | Imp Innovations Ltd | Polypeptides |
| JP7374883B2 (ja) | 2017-08-09 | 2023-11-07 | バイオベラティブ セラピューティクス インコーポレイテッド | 核酸分子およびその使用 |
| WO2019152692A1 (en) | 2018-02-01 | 2019-08-08 | Bioverativ Therapeutics, Inc. | Use of lentiviral vectors expressing factor viii |
| RS66972B1 (sr) * | 2018-05-18 | 2025-07-31 | Bioverativ Therapeutics Inc | Metode lečenja hemofilije a |
| BR112021001315A2 (pt) * | 2018-08-03 | 2021-04-27 | Sangamo Therapeutics, Inc. | parâmetros clínicos melhorados através da expressão do fator viii |
| CN119955796A (zh) | 2018-08-09 | 2025-05-09 | 比奥维拉迪维治疗股份有限公司 | 核酸分子及其用于非病毒基因疗法的用途 |
| IL280880B2 (en) | 2018-08-27 | 2025-04-01 | Regeneron Pharma | Using Raman Spectroscopy in Downstream Purification |
| CN113105562B (zh) * | 2018-09-26 | 2023-12-01 | 安源医药科技（上海）有限公司 | 突变型单链人凝血因子viii在制备融合蛋白中的应用 |
| CA3115535A1 (en) * | 2018-10-23 | 2020-04-30 | The Children's Hospital Of Philadelphia | Compositions and methods for modulating factor viii function |
| WO2020187969A1 (en) | 2019-03-19 | 2020-09-24 | CSL Behring Lengnau AG | Factor ix variants and uses thereof in therapy |
| US10654911B1 (en) * | 2019-04-02 | 2020-05-19 | Beijing Neoletix Biological Technology Co., Ltd. | Vector co-expressing truncated von Willebrand factor and factor VIII |
| EP3956456A1 (en) | 2019-04-17 | 2022-02-23 | Codiak BioSciences, Inc. | Compositions of exosomes and aav |
| EP3736286A1 (en) | 2019-05-09 | 2020-11-11 | Biotest AG | Single chain factor viii molecule |
| CN114007637A (zh) | 2019-06-19 | 2022-02-01 | 比奥维拉迪维治疗股份有限公司 | 用于治疗血友病和低骨矿物质密度的重组因子viii-fc |
| CN115279896A (zh) | 2019-09-30 | 2022-11-01 | 比奥维拉迪维治疗股份有限公司 | 慢病毒载体配制品 |
| MX2023000156A (es) | 2020-06-24 | 2023-02-16 | Bioverativ Therapeutics Inc | Metodos para la eliminacion de factor viii libre de preparaciones de vectores lentivirales modificados para expresar dicha proteina. |
| US20230174811A1 (en) | 2020-07-22 | 2023-06-08 | Ricoh Company, Ltd. | Ink set, printed matter, printing method, and printing device |
| CA3220564A1 (en) | 2021-06-23 | 2022-12-29 | Bioverativ Therapeutics Inc. | Formulations of factor viii chimeric proteins and uses thereof |
| AU2022334711A1 (en) | 2021-08-23 | 2024-04-04 | Bioverativ Therapeutics Inc. | Baculovirus expression system |
| EP4392443A1 (en) | 2021-08-23 | 2024-07-03 | Bioverativ Therapeutics Inc. | Optimized factor viii genes |
| CA3232988A1 (en) | 2021-09-30 | 2023-04-06 | Bioverativ Therapeutics Inc. | Nucleic acids encoding factor viii polypeptides with reduced immunogenicity |
| CN115873099B (zh) * | 2022-12-30 | 2023-10-20 | 福因医药科技(武汉)有限公司 | 一种改造的重组凝血因子viii及其应用 |
| CN116715752B (zh) * | 2023-06-16 | 2024-11-15 | 苏州诺洁贝生物技术有限公司 | 凝血因子fviii蛋白变体、表达载体和用途 |
Family Cites Families (168)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4179337A (en) | 1973-07-20 | 1979-12-18 | Davis Frank F | Non-immunogenic polypeptides |
| US4215051A (en) | 1979-08-29 | 1980-07-29 | Standard Oil Company (Indiana) | Formation, purification and recovery of phthalic anhydride |
| US4713339A (en) | 1983-01-19 | 1987-12-15 | Genentech, Inc. | Polycistronic expression vector construction |
| US4757006A (en) | 1983-10-28 | 1988-07-12 | Genetics Institute, Inc. | Human factor VIII:C gene and recombinant methods for production |
| US4965199A (en) | 1984-04-20 | 1990-10-23 | Genentech, Inc. | Preparation of functional human factor VIII in mammalian cells using methotrexate based selection |
| US4683202A (en) | 1985-03-28 | 1987-07-28 | Cetus Corporation | Process for amplifying nucleic acid sequences |
| US4965188A (en) | 1986-08-22 | 1990-10-23 | Cetus Corporation | Process for amplifying, detecting, and/or cloning nucleic acid sequences using a thermostable enzyme |
| US4683195A (en) | 1986-01-30 | 1987-07-28 | Cetus Corporation | Process for amplifying, detecting, and/or-cloning nucleic acid sequences |
| US5981216A (en) | 1985-04-01 | 1999-11-09 | Alusuisse Holdings A.G. | Transformed myeloma cell-line and a process for the expression of a gene coding for a eukaryotic polypeptide employing same |
| JPH0788399B2 (ja) | 1985-04-12 | 1995-09-27 | ジェネティックス・インスチチュ−ト・インコ−ポレ−テッド | 新規プロコアギュラント蛋白質 |
| KR910006424B1 (ko) | 1985-08-21 | 1991-08-24 | 인코텍스 비.브이 | 편성브리프(brief) 제조방법 |
| EP0253870B1 (en) | 1986-01-03 | 1993-03-31 | Genetics Institute, Inc. | Method for producing factor viii:c-type proteins |
| US5595886A (en) | 1986-01-27 | 1997-01-21 | Chiron Corporation | Protein complexes having Factor VIII:C activity and production thereof |
| US4800159A (en) | 1986-02-07 | 1989-01-24 | Cetus Corporation | Process for amplifying, detecting, and/or cloning nucleic acid sequences |
| US5610278A (en) | 1986-06-24 | 1997-03-11 | Novo Nordisk A/S | Process for producing a coagulation active complex of factor VIII fragments |
| US4912040A (en) | 1986-11-14 | 1990-03-27 | Genetics Institute, Inc. | Eucaryotic expression system |
| AU600575B2 (en) | 1987-03-18 | 1990-08-16 | Sb2, Inc. | Altered antibodies |
| CA1331157C (en) | 1987-04-06 | 1994-08-02 | Randal J. Kaufman | Method for producing factor viii:c-type proteins |
| US6060447A (en) | 1987-05-19 | 2000-05-09 | Chiron Corporation | Protein complexes having Factor VIII:C activity and production thereof |
| US6346513B1 (en) | 1987-06-12 | 2002-02-12 | Baxter Trading Gmbh | Proteins with factor VIII activity: process for their preparation using genetically-engineered cells and pharmaceutical compositions containing them |
| IL86693A (en) | 1987-06-12 | 1994-06-24 | Stichting Centraal Lab | Proteins with factor VIII activity, process for their preparation using genetically engineered cells and pharmaceutical compositions containing them |
| DE3720246A1 (de) | 1987-06-19 | 1988-12-29 | Behringwerke Ag | Faktor viii:c-aehnliches molekuel mit koagulationsaktivitaet |
| FR2619314B1 (fr) | 1987-08-11 | 1990-06-15 | Transgene Sa | Analogue du facteur viii, procede de preparation et composition pharmaceutique le contenant |
| US4994371A (en) | 1987-08-28 | 1991-02-19 | Davie Earl W | DNA preparation of Christmas factor and use of DNA sequences |
| US6780613B1 (en) | 1988-10-28 | 2004-08-24 | Genentech, Inc. | Growth hormone variants |
| US5004803A (en) | 1988-11-14 | 1991-04-02 | Genetics Institute, Inc. | Production of procoagulant proteins |
| SE465222C5 (sv) | 1989-12-15 | 1998-02-10 | Pharmacia & Upjohn Ab | Ett rekombinant, humant faktor VIII-derivat och förfarande för dess framställning |
| US20060122376A1 (en) | 1991-02-07 | 2006-06-08 | Chiron Corporation | Protein complexes having factor VIII:C activity and production thereof |
| US5846951A (en) | 1991-06-06 | 1998-12-08 | The School Of Pharmacy, University Of London | Pharmaceutical compositions |
| MX9204374A (es) | 1991-07-25 | 1993-03-01 | Idec Pharma Corp | Anticuerpo recombinante y metodo para su produccion. |
| US5364771A (en) | 1992-04-07 | 1994-11-15 | Emory University | Hybrid human/porcine factor VIII |
| US6376463B1 (en) | 1992-04-07 | 2002-04-23 | Emory University | Modified factor VIII |
| US5859204A (en) | 1992-04-07 | 1999-01-12 | Emory University | Modified factor VIII |
| US6037452A (en) | 1992-04-10 | 2000-03-14 | Alpha Therapeutic Corporation | Poly(alkylene oxide)-Factor VIII or Factor IX conjugate |
| US5563045A (en) | 1992-11-13 | 1996-10-08 | Genetics Institute, Inc. | Chimeric procoagulant proteins |
| SE504074C2 (sv) | 1993-07-05 | 1996-11-04 | Pharmacia Ab | Proteinberedning för subkutan, intramuskulär eller intradermal administrering |
| US5643575A (en) | 1993-10-27 | 1997-07-01 | Enzon, Inc. | Non-antigenic branched polymer conjugates |
| GB9422383D0 (en) | 1994-11-05 | 1995-01-04 | Wellcome Found | Antibodies |
| US6818439B1 (en) | 1994-12-30 | 2004-11-16 | Chiron Corporation | Methods for administration of recombinant gene delivery vehicles for treatment of hemophilia and other disorders |
| US6485726B1 (en) | 1995-01-17 | 2002-11-26 | The Brigham And Women's Hospital, Inc. | Receptor specific transepithelial transport of therapeutics |
| US6030613A (en) | 1995-01-17 | 2000-02-29 | The Brigham And Women's Hospital, Inc. | Receptor specific transepithelial transport of therapeutics |
| US6086875A (en) | 1995-01-17 | 2000-07-11 | The Brigham And Women's Hospital, Inc. | Receptor specific transepithelial transport of immunogens |
| US6096871A (en) | 1995-04-14 | 2000-08-01 | Genentech, Inc. | Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life |
| US5869046A (en) | 1995-04-14 | 1999-02-09 | Genentech, Inc. | Altered polypeptides with increased half-life |
| US6121022A (en) | 1995-04-14 | 2000-09-19 | Genentech, Inc. | Altered polypeptides with increased half-life |
| US5739277A (en) | 1995-04-14 | 1998-04-14 | Genentech Inc. | Altered polypeptides with increased half-life |
| SE9503380D0 (sv) | 1995-09-29 | 1995-09-29 | Pharmacia Ab | Protein derivatives |
| US6458563B1 (en) | 1996-06-26 | 2002-10-01 | Emory University | Modified factor VIII |
| AU3968897A (en) | 1996-08-02 | 1998-02-25 | Bristol-Myers Squibb Company | A method for inhibiting immunoglobulin-induced toxicity resulting from the use of immunoglobulins in therapy and in vivo diagnosis |
| WO1998023289A1 (en) | 1996-11-27 | 1998-06-04 | The General Hospital Corporation | MODULATION OF IgG BINDING TO FcRn |
| US6277375B1 (en) | 1997-03-03 | 2001-08-21 | Board Of Regents, The University Of Texas System | Immunoglobulin-like domains with increased half-lives |
| CA2225189C (en) | 1997-03-06 | 2010-05-25 | Queen's University At Kingston | Canine factor viii gene, protein and methods of use |
| GB9722131D0 (en) | 1997-10-20 | 1997-12-17 | Medical Res Council | Method |
| US6242195B1 (en) | 1998-04-02 | 2001-06-05 | Genentech, Inc. | Methods for determining binding of an analyte to a receptor |
| US6194551B1 (en) | 1998-04-02 | 2001-02-27 | Genentech, Inc. | Polypeptide variants |
| US6528624B1 (en) | 1998-04-02 | 2003-03-04 | Genentech, Inc. | Polypeptide variants |
| DE69937291T2 (de) | 1998-04-02 | 2008-07-10 | Genentech, Inc., South San Francisco | Antikörpervarianten und fragmente davon |
| GB9809951D0 (en) | 1998-05-08 | 1998-07-08 | Univ Cambridge Tech | Binding molecules |
| CA2341029A1 (en) | 1998-08-17 | 2000-02-24 | Abgenix, Inc. | Generation of modified molecules with increased serum half-lives |
| EP1006183A1 (en) | 1998-12-03 | 2000-06-07 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. | Recombinant soluble Fc receptors |
| US6358703B1 (en) | 1998-12-10 | 2002-03-19 | Bayer Corporation | Expression system for factor VIII |
| BR0008758A (pt) | 1999-01-15 | 2001-12-04 | Genentech Inc | Variantes de polipeptìdeos parentais com funçãoefetora alterada, polipeptìdeos, composição ácidonucleico isolado, vetor, célula hospedeira,método para produzir uma variante depolipeptìdeo, método para o tratamento de umadesordem em mamìferos e método para produziruma região fc variante |
| US6737056B1 (en) | 1999-01-15 | 2004-05-18 | Genentech, Inc. | Polypeptide variants with altered effector function |
| US7829085B2 (en) | 1999-07-14 | 2010-11-09 | Life Sciences Research Partners Vzw | Methods of treating hemostasis disorders using antibodies binding the C1 domain of factor VIII |
| JP2003526625A (ja) | 1999-07-23 | 2003-09-09 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | 血小板の活性化の調節 |
| CA2405550A1 (en) | 2000-04-12 | 2001-10-25 | Human Genome Sciences, Inc. | Albumin fusion proteins |
| WO2001087922A2 (en) | 2000-05-16 | 2001-11-22 | Lipoxen Technologies Limited | Derivatisation of proteins in aqueous solution |
| JP2001326635A (ja) | 2000-05-16 | 2001-11-22 | Matsushita Electric Ind Co Ltd | インターネットの課金システム |
| GB0029407D0 (en) | 2000-12-01 | 2001-01-17 | Affitech As | Product |
| PT1355919E (pt) | 2000-12-12 | 2011-03-02 | Medimmune Llc | Moléculas com semivida longa, composições que as contêm e suas utilizações |
| CA2440582A1 (en) | 2001-03-09 | 2002-10-03 | Dyax Corp. | Serum albumin binding moieties |
| TW503179B (en) | 2001-05-07 | 2002-09-21 | Benq Corp | Ink jetting device having bubble valve and the method thereof |
| JP2003110596A (ja) | 2001-09-28 | 2003-04-11 | Hitachi Ltd | データ通信サービス提供方法 |
| AU2002364586A1 (en) | 2001-12-21 | 2003-07-30 | Delta Biotechnology Limited | Albumin fusion proteins |
| KR101271635B1 (ko) | 2001-12-21 | 2013-06-12 | 휴먼 게놈 사이언시즈, 인코포레이티드 | 알부민 융합 단백질 |
| US20080194481A1 (en) | 2001-12-21 | 2008-08-14 | Human Genome Sciences, Inc. | Albumin Fusion Proteins |
| US20040002587A1 (en) | 2002-02-20 | 2004-01-01 | Watkins Jeffry D. | Fc region variants |
| US20040132101A1 (en) | 2002-09-27 | 2004-07-08 | Xencor | Optimized Fc variants and methods for their generation |
| US20040018557A1 (en) | 2002-03-01 | 2004-01-29 | Immunomedics, Inc. | Bispecific antibody point mutations for enhancing rate of clearance |
| US7317091B2 (en) | 2002-03-01 | 2008-01-08 | Xencor, Inc. | Optimized Fc variants |
| CN100343393C (zh) | 2002-03-15 | 2007-10-17 | 布赖汉姆妇女医院 | 适合治疗剂全身性递送的中央气道给药 |
| JP4459810B2 (ja) | 2002-08-14 | 2010-04-28 | マクロジェニクス，インコーポレーテッド | ＦｃγＲＩＩＢ特異的抗体とその利用法 |
| AU2003275103A1 (en) | 2002-09-17 | 2004-04-08 | Diffusion Science, Inc. | Electrochemical generation, storage and reaction of hydrogen and oxygen using gas permeable catalyst-coated hollow microspheres |
| CA2499816C (en) | 2002-09-27 | 2013-07-30 | Xencor, Inc. | Optimized fc variants and methods for their generation |
| AU2003286467B2 (en) | 2002-10-15 | 2009-10-01 | Abbvie Biotherapeutics Inc. | Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis |
| GB2395337B (en) | 2002-11-14 | 2005-12-28 | Gary Michael Wilson | Warning Unit |
| EP1587540B1 (en) | 2003-01-09 | 2021-09-15 | MacroGenics, Inc. | IDENTIFICATION AND ENGINEERING OF ANTIBODIES WITH VARIANT Fc REGIONS AND METHODS OF USING SAME |
| US7041635B2 (en) | 2003-01-28 | 2006-05-09 | In2Gen Co., Ltd. | Factor VIII polypeptide |
| AU2004215912B2 (en) | 2003-02-26 | 2009-03-26 | Nektar Therapeutics | Polymer-factor VIII moiety conjugates |
| WO2004076484A1 (en) | 2003-02-27 | 2004-09-10 | National Research Council Of Canada | Peptide inhibitors of thrombin as potent anticoagulants |
| KR100851263B1 (ko) | 2003-02-28 | 2008-08-08 | 가부시키가이샤 구라레 | 경화성 수지 조성물 |
| US8388955B2 (en) | 2003-03-03 | 2013-03-05 | Xencor, Inc. | Fc variants |
| US20090010920A1 (en) | 2003-03-03 | 2009-01-08 | Xencor, Inc. | Fc Variants Having Decreased Affinity for FcyRIIb |
| US7348004B2 (en) | 2003-05-06 | 2008-03-25 | Syntonix Pharmaceuticals, Inc. | Immunoglobulin chimeric monomer-dimer hybrids |
| DE602004031390D1 (de) | 2003-05-06 | 2011-03-24 | Syntonix Pharmaceuticals Inc | Gerinnungsfaktor VII-Fc chimäre Proteine zur Behandlung von hämostatischen Krankheiten |
| TWI353991B (en) | 2003-05-06 | 2011-12-11 | Syntonix Pharmaceuticals Inc | Immunoglobulin chimeric monomer-dimer hybrids |
| KR101113726B1 (ko) | 2003-08-12 | 2012-02-27 | 리폭센 테크놀로지즈 리미티드 | 단백질 유도 및 컨쥬게이션용 시알산 유도체 |
| JP2007503838A (ja) * | 2003-09-05 | 2007-03-01 | ジーティーシー バイオセラピューティクス， インコーポレイティド | トランスジェニック動物の乳汁中での融合タンパク質の産生方法 |
| GB0324368D0 (en) | 2003-10-17 | 2003-11-19 | Univ Cambridge Tech | Polypeptides including modified constant regions |
| US7211559B2 (en) | 2003-10-31 | 2007-05-01 | University Of Maryland, Baltimore | Factor VIII compositions and methods |
| CA2545603A1 (en) | 2003-11-12 | 2005-05-26 | Biogen Idec Ma Inc. | Neonatal fc receptor (fcrn)-binding polypeptide variants, dimeric fc binding proteins and methods related thereto |
| WO2005077981A2 (en) | 2003-12-22 | 2005-08-25 | Xencor, Inc. | Fc POLYPEPTIDES WITH NOVEL Fc LIGAND BINDING SITES |
| CA2552788C (en) | 2004-01-12 | 2013-09-24 | Applied Molecular Evolution, Inc. | Fc region variants |
| EP2053062A1 (en) | 2004-03-24 | 2009-04-29 | Xencor, Inc. | Immunoglobin variants outside the Fc region |
| WO2005123780A2 (en) | 2004-04-09 | 2005-12-29 | Protein Design Labs, Inc. | Alteration of fcrn binding affinities or serum half-lives of antibodies by mutagenesis |
| WO2006085967A2 (en) | 2004-07-09 | 2006-08-17 | Xencor, Inc. | OPTIMIZED ANTI-CD20 MONOCONAL ANTIBODIES HAVING Fc VARIANTS |
| BRPI0510674A (pt) | 2004-07-15 | 2007-12-26 | Xencor Inc | variantes fc otimizadas |
| US7566701B2 (en) | 2004-09-07 | 2009-07-28 | Archemix Corp. | Aptamers to von Willebrand Factor and their use as thrombotic disease therapeutics |
| WO2006047350A2 (en) | 2004-10-21 | 2006-05-04 | Xencor, Inc. | IgG IMMUNOGLOBULIN VARIANTS WITH OPTIMIZED EFFECTOR FUNCTION |
| KR20070092754A (ko) | 2004-12-27 | 2007-09-13 | 백스터 인터내셔널 인코포레이티드 | 중합체 - 폰 빌레브란트 인자 - 접합체 |
| GB0516091D0 (en) | 2005-08-04 | 2005-09-14 | Haemostatix Ltd | Therapeutic agent |
| KR20080071119A (ko) | 2005-08-12 | 2008-08-01 | 휴먼 게놈 사이언시즈, 인코포레이티드 | 알부민 융합 단백질 |
| US7846445B2 (en) | 2005-09-27 | 2010-12-07 | Amunix Operating, Inc. | Methods for production of unstructured recombinant polymers and uses thereof |
| EP1816201A1 (en) | 2006-02-06 | 2007-08-08 | CSL Behring GmbH | Modified coagulation factor VIIa with extended half-life |
| EP1996937A4 (en) | 2006-03-06 | 2009-04-08 | Amunix Inc | GENETIC PACKS AND USES THEREOF |
| EP2032607B2 (en) | 2006-06-14 | 2017-02-22 | CSL Behring GmbH | Proteolytically cleavable fusion protein comprising a blood coagulation factor |
| US7939632B2 (en) | 2006-06-14 | 2011-05-10 | Csl Behring Gmbh | Proteolytically cleavable fusion proteins with high molar specific activity |
| EP1867660A1 (en) | 2006-06-14 | 2007-12-19 | CSL Behring GmbH | Proteolytically cleavable fusion protein comprising a blood coagulation factor |
| AU2007294805A1 (en) | 2006-09-14 | 2008-03-20 | Human Genome Sciences, Inc. | Albumin fusion proteins |
| JP2010505874A (ja) | 2006-10-03 | 2010-02-25 | ノヴォ ノルディスク アー／エス | ポリペプチドコンジュゲートの精製方法 |
| US20100041872A1 (en) | 2006-10-04 | 2010-02-18 | Defrees Shawn | Glycerol linked pegylated sugars and glycopeptides |
| EP1935430A1 (en) | 2006-12-22 | 2008-06-25 | CSL Behring GmbH | Modified coagulation factors with prolonged in vivo half-life |
| EP3231440A1 (en) | 2006-12-22 | 2017-10-18 | CSL Behring GmbH | Modified coagulation factors with prolonged in vivo half-life |
| DE602008005596D1 (de) | 2007-06-21 | 2011-04-28 | Univ Muenchen Tech | Biologisch aktive proteine mit erhöhter in-vivo- und/oder in-vitro-stabilität |
| BRPI0815416A2 (pt) | 2007-08-15 | 2014-10-21 | Amunix Inc | Composições e métodos para modificar propriedades de polipeptídeos biologicamente ativos |
| CA2703948A1 (en) | 2007-11-01 | 2009-05-07 | University Of Rochester | Recombinant factor viii having increased stability |
| BRPI0820271A2 (pt) | 2007-11-09 | 2015-05-26 | Baxter Int | Métodos de aumentar a sobrevivência de uma proteína de coagulação pela inibição da interação com um receptor de depuração, de aumentar a sobrevivência de fator viii que inibe receptores de depruração de proteína de coagulação, de tratar um indivíduo com uma doença de coagulação sanguínea, e de tratar uma doença que tem por característica uma deficiência de fator viii em um indivíduo, e, proteína de ...métodos de aumentar a sobrevivência de uma proteína de coagulação pela inibição da interação com um receptor de depuração, de aumentar a sobrevivência de fator viii pela inibição da interação com um receptor de depuração, de preparar uma composição que inibe receptores de depuração de proteína de coagulação, de tratar um indivíduo com uma doença de coagulação sanguínea, e de tratar uma doença que tem por característica uma deficiência de fator viii em um indivíduo, e, proteína de coagulação modificada. |
| NZ586383A (en) * | 2007-12-28 | 2012-11-30 | Baxter Int | Recombinant vwf formulations |
| KR100981092B1 (ko) | 2008-02-29 | 2010-09-08 | 고려대학교 산학협력단 | 제8 혈액응고 인자와 폰 빌리 블란트 인자 변이체의 재조합발현 벡터 시스템 |
| EP2259702A4 (en) * | 2008-03-25 | 2017-04-19 | Johnson Controls Technology Company | Vehicular trim applications using film adhesive in lieu of stitching |
| CN103739712B (zh) | 2008-06-24 | 2016-10-05 | 德国杰特贝林生物制品有限公司 | 具有延长的体内半衰期的因子viii、冯·维勒布兰德因子或它们的复合物 |
| WO2010060081A1 (en) | 2008-11-24 | 2010-05-27 | Bayer Healthcare Llc | Method of determining pegylated blood coagulation factor activity in a silica-based activated partial thromboplastin time assay |
| US8680050B2 (en) | 2009-02-03 | 2014-03-25 | Amunix Operating Inc. | Growth hormone polypeptides fused to extended recombinant polypeptides and methods of making and using same |
| WO2010091122A1 (en) | 2009-02-03 | 2010-08-12 | Amunix, Inc. | Extended recombinant polypeptides and compositions comprising same |
| US8703717B2 (en) | 2009-02-03 | 2014-04-22 | Amunix Operating Inc. | Growth hormone polypeptides and methods of making and using same |
| CN102427823A (zh) | 2009-03-24 | 2012-04-25 | 拜耳医药保健有限公司 | 因子viii变体及使用方法 |
| EP2990051B1 (en) | 2009-04-10 | 2016-10-26 | Tufts Medical Center, Inc. | Par-1 activation by metalloproteinase-1 (mmp-1) |
| AU2010258898B8 (en) | 2009-06-08 | 2015-02-05 | Amunix Operating Inc. | Glucose-regulating polypeptides and methods of making and using same |
| AU2010258892B2 (en) | 2009-06-08 | 2015-08-13 | Amunix Operating Inc. | Growth hormone polypeptides and methods of making and using same |
| US8450905B2 (en) * | 2009-07-23 | 2013-05-28 | New Scale Technologies | Methods for controlling velocity of at least partially resonant actuators systems and systems thereof |
| CA2770609A1 (en) | 2009-08-20 | 2011-02-24 | Csl Behring Gmbh | Albumin fused coagulation factors for non-intravenous administration in the therapy and prophylactic treatment of bleeding disorders |
| BR112012004094A2 (pt) | 2009-08-24 | 2016-03-08 | Amunix Operating Inc | composições de fator vii de coagulação e métodos para fazer e usar as mesmas |
| WO2011028344A2 (en) | 2009-08-25 | 2011-03-10 | Amunix Operating Inc. | Interleukin-1 receptor antagonist compositions and methods of making and using same |
| JP5544219B2 (ja) | 2009-09-24 | 2014-07-09 | 富士フイルム株式会社 | 内視鏡システム |
| MX2012005527A (es) * | 2009-11-13 | 2012-08-08 | Grifols Therapeutics Inc | Preparaciones que contienen el factor de von willebrand (fvw) procedimientos, kits y aplicaciones relacionados con las mismas. |
| WO2011062614A1 (en) | 2009-11-20 | 2011-05-26 | Tonix Pharmaceuticals, Inc. | Methods and compositions for treating symptoms associated with post-traumatic stress disorder using cyclobenzaprine |
| MX353233B (es) | 2009-12-06 | 2018-01-08 | Bioverativ Therapeutics Inc | Polipéptidos híbridos y quiméricos del factor viii-fc, y métodos de uso de los mismos. |
| WO2011084808A2 (en) | 2009-12-21 | 2011-07-14 | Amunix Operating Inc. | Bifunctional polypeptide compositions and methods for treatment of metabolic and cardiovascular diseases |
| EP2536753B1 (en) | 2010-02-16 | 2017-12-20 | Novo Nordisk A/S | Factor viii molecules with reduced vwf binding |
| EP2536754A1 (en) | 2010-02-16 | 2012-12-26 | Novo Nordisk A/S | Factor viii fusion protein |
| WO2011123830A2 (en) | 2010-04-02 | 2011-10-06 | Amunix Operating Inc. | Alpha 1-antitrypsin compositions and methods of making and using same |
| TWI619713B (zh) | 2010-04-21 | 2018-04-01 | 普雷辛肯公司 | 用於激酶調節的化合物和方法及其適應症 |
| JP6148979B2 (ja) | 2010-05-20 | 2017-06-14 | アラーガン、インコーポレイテッドＡｌｌｅｒｇａｎ，Ｉｎｃｏｒｐｏｒａｔｅｄ | 分解性クロストリジウム毒素 |
| WO2012006635A1 (en) | 2010-07-09 | 2012-01-12 | Biogen Idec Hemophilia Inc. | Processable single chain molecules and polypeptides made using same |
| US9611310B2 (en) | 2010-07-09 | 2017-04-04 | Bioverativ Therapeutics Inc. | Systems for factor VIII processing and methods thereof |
| US20130017997A1 (en) * | 2010-08-19 | 2013-01-17 | Amunix Operating Inc. | Factor VIII Compositions and Methods of Making and Using Same |
| EA035323B1 (ru) | 2012-01-12 | 2020-05-28 | Биовератив Терапьютикс Инк. | Полипептиды химерного фактора viii и их применение |
| HRP20221531T1 (hr) | 2012-02-15 | 2023-02-17 | Bioverativ Therapeutics Inc. | Pripravci faktora viii i postupci dobivanja i korištenja istih |
| LT2822577T (lt) | 2012-02-15 | 2019-03-25 | Bioverativ Therapeutics Inc. | Rekombinantiniai faktoriaus viii baltymai |
| US20150080309A1 (en) | 2012-04-24 | 2015-03-19 | Nova Nordisk A/S | Compounds Suitable for Treatment of Haemophilia |
| US10138291B2 (en) | 2012-07-11 | 2018-11-27 | Bioverativ Therapeutics Inc. | Factor VIII complex with XTEN and von Willebrand Factor protein, and uses thereof |
| US9832881B2 (en) * | 2013-04-19 | 2017-11-28 | Inktec Co., Ltd. | Method of manufacturing transparent electrode film for display and transparent electrode film for display |
| DK2796145T3 (da) | 2013-04-22 | 2018-01-29 | Csl Ltd | Et kovalent kompleks af von Willebrand-faktor og faktor VIII linket af en disulfidbro |
| WO2014210448A1 (en) | 2013-06-27 | 2014-12-31 | The Board Of Regents Of The University Of Texas System | Compositions and methods relating to myomaker-induced muscle cell fusion |
| WO2014210558A1 (en) | 2013-06-28 | 2014-12-31 | Biogen Idec Ma Inc. | Thrombin cleavable linker with xten and its uses thereof |
| WO2014210547A1 (en) | 2013-06-28 | 2014-12-31 | Biogen Idec Ma Inc. | Thrombin cleavable linker |
| DK3091997T5 (da) | 2014-01-10 | 2024-10-14 | Bioverativ Therapeutics Inc | Kimære faktor viii-proteiner og anvendelser deraf |
| EP3588013A1 (de) | 2018-06-26 | 2020-01-01 | XelectriX Power GmbH | Verfahren zur abgabe von elektrischer energie |
-
2015
- 2015-01-09 DK DK15735473.9T patent/DK3091997T5/da active
- 2015-01-09 CN CN202310334224.5A patent/CN116731201A/zh active Pending
- 2015-01-09 LT LTEPPCT/US2015/010738T patent/LT3091997T/lt unknown
- 2015-01-09 CN CN202310343186.XA patent/CN116621991A/zh active Pending
- 2015-01-09 FI FIEP22181403.1T patent/FI4176894T3/fi active
- 2015-01-09 CN CN201580009942.9A patent/CN106456718B/zh active Active
- 2015-01-09 SG SG10201913697UA patent/SG10201913697UA/en unknown
- 2015-01-09 PT PT157354739T patent/PT3091997T/pt unknown
- 2015-01-09 HU HUE15735473A patent/HUE059820T2/hu unknown
- 2015-01-09 HU HUE22181403A patent/HUE066567T2/hu unknown
- 2015-01-09 LT LTEP22181403.1T patent/LT4176894T/lt unknown
- 2015-01-09 WO PCT/US2015/010738 patent/WO2015106052A1/en not_active Ceased
- 2015-01-09 PT PT221814031T patent/PT4176894T/pt unknown
- 2015-01-09 MY MYPI2016001276A patent/MY192481A/en unknown
- 2015-01-09 RS RS20240549A patent/RS65533B1/sr unknown
- 2015-01-09 SI SI201531867T patent/SI3091997T1/sl unknown
- 2015-01-09 KR KR1020167021744A patent/KR102409250B1/ko active Active
- 2015-01-09 PL PL15735473.9T patent/PL3091997T3/pl unknown
- 2015-01-09 MX MX2016008958A patent/MX389878B/es unknown
- 2015-01-09 MY MYPI2022001172A patent/MY204756A/en unknown
- 2015-01-09 DK DK22181403.1T patent/DK4176894T3/da active
- 2015-01-09 CN CN202510297383.1A patent/CN120209161A/zh active Pending
- 2015-01-09 US US15/110,673 patent/US11192936B2/en active Active
- 2015-01-09 HR HRP20240640TT patent/HRP20240640T1/hr unknown
- 2015-01-09 UA UAA201607049A patent/UA120917C2/uk unknown
- 2015-01-09 RS RS20220879A patent/RS63583B1/sr unknown
- 2015-01-09 CA CA2935954A patent/CA2935954A1/en active Pending
- 2015-01-09 NZ NZ721544A patent/NZ721544A/en unknown
- 2015-01-09 CN CN202310324943.9A patent/CN117106095A/zh active Pending
- 2015-01-09 EA EA201691111A patent/EA201691111A1/ru unknown
- 2015-01-09 ES ES15735473T patent/ES2927475T3/es active Active
- 2015-01-09 EP EP22181403.1A patent/EP4176894B1/en active Active
- 2015-01-09 HR HRP20220960TT patent/HRP20220960T1/hr unknown
- 2015-01-09 BR BR112016015512-2A patent/BR112016015512B1/pt active IP Right Grant
- 2015-01-09 SI SI201532015T patent/SI4176894T1/sl unknown
- 2015-01-09 PL PL22181403.1T patent/PL4176894T3/pl unknown
- 2015-01-09 EP EP15735473.9A patent/EP3091997B1/en active Active
- 2015-01-09 IL IL246476A patent/IL246476B/en unknown
- 2015-01-09 SG SG11201605242YA patent/SG11201605242YA/en unknown
- 2015-01-09 IL IL282168A patent/IL282168B2/en unknown
- 2015-01-09 ES ES22181403T patent/ES2982051T3/es active Active
- 2015-01-09 PH PH1/2016/501323A patent/PH12016501323B1/en unknown
- 2015-01-09 EP EP24157036.5A patent/EP4389139A3/en active Pending
- 2015-01-09 AU AU2015204646A patent/AU2015204646B2/en active Active
- 2015-01-09 JP JP2016545930A patent/JP6749836B2/ja active Active
- 2015-01-09 SG SG10201805924PA patent/SG10201805924PA/en unknown
- 2015-01-09 CN CN202210167747.0A patent/CN114736305B/zh active Active
-
2016
- 2016-07-07 MX MX2022001134A patent/MX2022001134A/es unknown
-
2020
- 2020-07-03 JP JP2020115424A patent/JP6906882B2/ja active Active
- 2020-11-25 AU AU2020277146A patent/AU2020277146B2/en active Active
-
2021
- 2021-02-03 JP JP2021015485A patent/JP7104194B2/ja active Active
- 2021-11-05 US US17/519,719 patent/US20220275057A1/en active Pending
-
2022
- 2022-06-20 JP JP2022098923A patent/JP7612637B2/ja active Active
-
2024
- 2024-07-30 AU AU2024205200A patent/AU2024205200A1/en active Pending
- 2024-12-10 HU HUS2400043C patent/HUS2400043I1/hu unknown
- 2024-12-10 NL NL301303C patent/NL301303I2/nl unknown
- 2024-12-11 FI FIC20240043C patent/FIC20240043I1/fi unknown
- 2024-12-12 NO NO2024057C patent/NO2024057I1/no unknown
- 2024-12-13 LT LTPA2024536C patent/LTPA2024536I1/lt unknown
- 2024-12-13 FR FR24C1052C patent/FR24C1052I1/fr active Active
- 2024-12-24 JP JP2024227131A patent/JP2025036503A/ja active Pending
-
2025
- 2025-01-17 US US19/029,777 patent/US20250289869A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7612637B2 (ja) | 第ｖｉｉｉ因子キメラタンパク質及びその使用 | |
| JP7682968B2 (ja) | ＸＴＥＮおよびｖｏｎ Ｗｉｌｌｅｂｒａｎｄ因子タンパク質を有する第ＶＩＩＩ因子の複合体、および、その使用 | |
| EP3033097B1 (en) | Factor viii-xten fusions and uses thereof | |
| HK40113039A (en) | Factor viii chimeric proteins and uses thereof | |
| HK40092414A (en) | Factor viii chimeric proteins and uses thereof | |
| HK40092414B (en) | Factor viii chimeric proteins and uses thereof | |
| HK40099494A (en) | Factor viii complex with xten and von willebrand factor protein, and uses thereof | |
| HK1230526A1 (en) | Factor viii chimeric proteins and uses thereof | |
| HK1230526B (en) | Factor viii chimeric proteins and uses thereof | |
| HK1211228B (en) | Factor viii complex with xten and von willebrand factor protein, and uses thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20200108 |
|
| EEER | Examination request |
Effective date: 20200108 |
|
| EEER | Examination request |
Effective date: 20200108 |
|
| EEER | Examination request |
Effective date: 20200108 |
|
| EEER | Examination request |
Effective date: 20200108 |
|
| EEER | Examination request |
Effective date: 20200108 |
|
| EEER | Examination request |
Effective date: 20200108 |
|
| EEER | Examination request |
Effective date: 20200108 |
|
| EEER | Examination request |
Effective date: 20200108 |
|
| EEER | Examination request |
Effective date: 20200108 |
|
| EEER | Examination request |
Effective date: 20200108 |